[Consortium for detection and management of lung damage induced by bleomycin]. / Consortium de détection et prise en charge des atteintes pulmonaires induites par la bléomycine.
Bull Cancer
; 103(7-8): 651-61, 2016.
Article
em Fr
| MEDLINE
| ID: mdl-27241272
ABSTRACT
Bleomycin is a cytotoxic antibiotic and a component of chemotherapy regimens of germ cell tumors and lymphoma. Bleomycin lung injuries occur in 10% of patients, and lead to severe interstitial pneumonia in 3% of patients. Pulmonary toxicity is related to endothelial cells injury induce by free radicals and inflammatory cytokines. Diagnosis of bleomycin-induced lung toxicity is based on the combination of clinical and radiological features, and requires to rule out differential diagnoses including pneumocystis. "Bleomycin-induced pneumonitis" is the most frequent pattern; eosinophilic pneumonitis and organizing pneumonia are rarer. Occurrence of bleomycin lung toxicity requires an immediate and often permanent discontinuation. Treatment is based on steroid. Regular clinical and pulmonary function tests monitoring are mandatory for early detection of bleomycin-induced lung toxicity.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pneumonia
/
Bleomicina
/
Antibióticos Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Risk_factors_studies
/
Screening_studies
Limite:
Humans
Idioma:
Fr
Revista:
Bull Cancer
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
França